Delphine Chen, MD
My mother and grandfather both had cancer. While my mother survived, my grandfather passed away. I’ve seen firsthand how hard it is for patients to go through cancer treatments. It’s an emotionally and physically exhausting journey, both for the patients themselves and for those who love them. Going through those experiences serves as a constant reminder that people facing cancer need support across multiple areas of their lives as they go through imaging studies and treatments.
I want to know the whole you, not just your medical condition. I like taking the time to understand your story. Cancer treatment is complicated, and the better I know you, the better I can provide care on all fronts. My area of medicine is highly specialized, so I strive to clearly explain how nuclear medicine therapies work and how these therapies fit within the context of other available options. I believe in empowering you to be an active participant in your care and providing all the information you need to thoroughly understand your treatment. Your questions make me a better physician.
I am a board-certified physician in nuclear medicine, a type of imaging that uses small doses of radioactive materials to assess, diagnose and treat diseases. My expertise spans several nuclear medicine-based diagnostic tests and procedures such as positron emission tomography (PET). At SCCA, I also serve as the director of molecular imaging. This fast-growing field examines how the body is functioning at a molecular or cellular level. Molecular imaging, which has its roots in nuclear medicine, provides insight about how diseases like cancer behave, which in turn can affect treatment decisions.
In addition to providing care, I am also an active researcher. One area of interest is how PET scan tracers can be used to determine whether or not a cell is dying. The idea is that this information could help determine how a tumor is responding to therapy and therefore guide treatment. I led the first in-human trial of these tracers, which has served as the foundation for multiple clinical trials currently being conducted at three major U.S. medical centers. These clinical trials are focused on how we can best use this tracer to identify patients who may respond to anticancer drugs called PARP inhibitors. My colleagues and I plan to expand that research at SCCA.
Dr. Chen has been recognized as a Top Doctor in this peer-nominated award.
Dr. Chen received this award in 2009. Funded by the Society of Nuclear Medicine and Molecular Imaging, the award honors the accomplishments of young researchers in the field of nuclear medicine.
Dr. Chen received this award in 2006 in support of her research into PET imaging and how it can be used to drive cancer treatment decisions.
Neuroendocrine tumors (NETs) pose unique obstacles for oncologists and radiologists. Many people with this rare condition often do not experience symptoms. Others show signs similar to other diseases, making diagnosis difficult. And treatment requires carefully calibrated techniques to achieve the best possible outcomes.
We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.
Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.
SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.
GU Oncology Now spoke to Delphine Chen, MD, Director of Molecular Imaging, Seattle Cancer Care Alliance, who spoke to us about the use of PSMA-Targeted PET imaging modalities for detecting prostate cancer.
SCCA’s Dr. Delphine Chen, MD, discussed recommendations for PET imaging for lung disease.
Your care team
SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.